Treatments in Development
What's in development, who's developing it, and what phase it's reached. Looking for a recruiting study instead? Find My Trial →
About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
807 compounds
[1-13C] glucose
[13C9, 15N1]-glucagon
[18F]-PI-2620
[18F]-PI-2620
[2-13C] glucose
[6,6-2H2] glucose
AAV9-GLB1
Abaloparatide
ABBV-295
ABP-671
AC2993
ACCG-2671
ACCG-2671
Acetyl-l-carnitine
Active comparator Taurine
Adalimumab
Adjuvant IM Therapy
AG-181
AG-181
AKM Lab-01
Aleniglipron
GSBR-1290
Allisartan Isoproxil
Allopurinol
ALN-2232
ALN-2232
ALN-4324
ALN-4324
ALN-ANG3
ALN-APP
ALN-CIDEB
ALN-PNP
ALN-SOD
Alpha Tocopherol
Alpha-Lipoic Acid
ALV-100
ALV-100
Amlodipine Besylate
AMT-191
AMT-191
AMX0035
AMX0035
Angiotensin Ii
Anti-thymocyte globulin
Antihyperglycemic therapy
AP-306
Apelin
Apraglutide
ARGX-119
ARGX-119
ARO-INHBE
ASC30
ASC30
ASC30 A1
ASC30 A1
ASC35 B, for use
ASC35 B, for use
Asedebart
Aspirin
AT2221
ATB200
Atezolizumab
ATL-001
Atorvastatin and ezetimibe
Atorvastatin Calcium Trihydrate
ATR 1072
ATR 1072
atumelnant
AZ-3102
AZ-3102
AZD0780
AZD6234
AZD9550
AZD9550
Baricitinib
BBI-001
Beinaglutide
Bemiparin 3500
Bempedoic Acid
Bendamustine Hydrochloride
Best medical management
BGE-102
BGE-102
BGM0504
BGM0504 Administered
BGM0504 Administered
BI 10773
BI 3034701
BI 3034701
BI 456906
Biological check-up
Biological sampling
blood analysis
Blood samples
Bortezomib
Brenipatide
Busulfan
Bydureon BCise
CagriSema
Cannabidiol
CBL-514
CBL-514
Chlorhexidine care
Chlorthalidone with potassium chloride
Cholecalciferol
Chronocort®
clofutriben
CNP-103
CNP-103
Colchicine
Combined contraceptive
Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2
Continue GLP/GIP
controlled-ileal-release nicotinic acid as multiple dose /day
Crinecerfont
CSL300
CSL300
CTX310
CTX310
CX11
Cyclophosphamide
Cyproheptadine Hydrochloride
DA-1726
Dapagliflozin
Daratumumab
Daridorexant
Darifenacin Hydrobromide
DCR-PHXC
DeltaGold® Tocotrienol 70%
Denosumab
Deuterated water
Dextrose 20%
Dextrose infusion
Dextrose Monohydrate
Diabetes Medication
Diane-35
Diazoxide suspension, per kg per dose
Dilaudid Product
Donanemab
Donepezil Hydrochloride
Dose escalation to 2 mg semaglutide weekly then no semaglutide
Dotinurad
Doxecitine and Doxribtimine
Doxycyclin
DPP-4 inhibitor
Droxidopa Product
Dual GIP/GLP-1 Receptor Agonist Tirzepatide
dulaglutide
ECC4703
ECC5004
Ecnoglutide
Elamipretide
Elecoglipron
Elecoglipron Reference Formulation Dose A
Elecoglipron Reference Formulation Dose B
Elecoglipron Test formulation 1 Dose A
Elecoglipron Test formulation 1 Dose B
Elecoglipron Test formulation 2 Dose A
Elecoglipron Test formulation 2 Dose B
Elemental Iron
Eloralintide
LY3841136
Eltrombopag Olamine
Empagliflozin
empagliflozin (Jardiance)
Enicepatide
Enlicitide
Ensure Enlive Advanced Nutrition Shake
Ensure Surgery Immunonutrition Shake
Envarsus Product
Epalrestat
Ephedrine Sulfate
Eplerenone
Estrone
Evinacumab
Evolocumab
Exenatide
Exendin-
Exendin-9,39
Ezetimibe
Febuxostat
Fecal Microbiota Transplantation
Ferinject
Ferric Citrate
Ferric Derisomaltose
Ferrous Fumarate
Ferrous Sulfate Product
FGF23-related hypophosphataemic rickets and osteomalacia
Finerenone
Fingolimod Hydrochloride
First-Line Dara-BorCyD Treatment
Fixed-Dose Combination Strategy
Fludarabine Phosphate
Fluorouracil
Fuling Yunhua Granules
Fulvestrant
G-Pen
Gabapentin
GIP-A
GIP[3-30]NH2
glepaglutide
Glibenclamide
GLP-1 (7-36) amide
GLP-1 medication
GLP-1 RAs
GLP-1 Stop for 1 week
GLP-1/FGF21 dual agonist
GLP-1A
GLP-1RA
GlucaGen
Glucagon for Injection
Glucagon Infusion
Glucagon-like peptide-1 receptor agonist:Semaglutide
Glucagon, 0-0.5 ng/kg/min
Glucose
glucose dependent insulinotropic polypeptide
Glycerol
GnRH antagonist
GnRHa
Gold
Growth Hormone, Human
GS-4571
GS-4571
GUB-UCN2
Guideline Directed Medical Therapy for Heart Failure
guideline-based treatment for DM
GVHD Regimen A: UCB Recipients
GVHD Regimen B: BM Recipients
GZC8072
GZC8072
GZR18
GZR33 Injection
HDM1002 100 mg
HDM1005
HDM1005
HDM1005 1
HDM1005 2
HDM1702
High-Intensity Statin Therapy
HM11260C
HM15275
HPN-100
HRS-1301
HRS-1301
HRS-4729
HRS-4729
HRS-7249
HRS-7249
HRS-7535
HRS-7535
HRS9531 Tablet
HS235
HS235
Hycet - /
Hyperinsulinemic, euglycemic clamp
IBI3032
IBI3032
IBI3042
IBI3042
IN026 Injection
Inavolisib
Inclisiran
Inclisiran sodium (equivalent to inclisiran) in
Incretins
Indomethacin
Injected GLP-1 Receptor Agonists and Dual Agonists
Insulin + semaglutide treatment
Insulin Aspart
Insulin Degludec
Insulin glargine
Insulin icodec
insulin infusion
Insulin Lispro
Intranasal insulin
Intravenous saline
Investigational Drug: IBI3042
Investigational Drug: IBI3042
Islet cells
ITCA 650
Ivarmacitinib
Ixazomib
Jiedu Huayu Prescription
JMT206
JMT206
JNJ-79635322
JNJ-79635322
JR-446
JR-446
KBP-336
Ketorolac Tromethamine
KK8123
KK8123
KRRO-121
KRRO-121
Lactate
Lactulose
LAE102 in combined with LAE103
LAE102 in combined with LAE103
LAE103
LAE103
LAF 237
Laroprovstat
Laroprovstat/Rosuvastatin 1
Laroprovstat/Rosuvastatin 2
LCI699
LCZ 696
Lenalidomide
Letrozole
Leucovorin Calcium
Levacetylleucine
Liraglutide
Liraglutide / Semaglutide
Lixisenatide
Locally available low-dose semaglutide
Lorazepam
Losartan Potassium
Lumateperone
Lurasidone Hydrochloride
LY2189265
LY2606368
LY3305677
LY3305677
LY3457263
LY3532226
LY3549492
LY3549492
LY3971297
LY3971297
LY4057996
LY4057996
LY4256984
LY4256984
LY4329090
LY4329090
LY900014
Macupatide
Magnesium Citrate
Maridebart Cafraglutide
Mazdutide
Memantine Hydrochloride
MET097
MET233 and MET097
Metformin
Metformin Hydrochloride
Methotrexate Sodium
Methylprednisolone
Metreleptin
Metyrapone
Metyrapone And Hydrocortisone
Mibavademab
Micro-glucagon
Mirabegron
Mirikizumab
Mitapivat
MK-0616
MK-4082
MK-4082
MNCs
moderate- or high-intensity statin/ rosuvastatin
Montelukast
Moxifloxacin Hydrochloride
MZE782
MZE782
Naltrexone and Bupropion Combination
Naltrexone Hydrochloride
Naltrexone-Bupropion
Napazimone
NB-4746
NB-4746
NB-4746 High dose
NB-4746 High dose
NB-4746 Low dose
NB-4746 Low dose
Nicotine Replacement Therapy
NIO752
NIO752
NLY01
NNC0487-0111
NNC0519-0130
NNC0662-0419
NNC0662-0419
Nomlabofusp
Non-GLP-1 RA based glucose lowering drugs
Norepinephrine Bitartrate
Norgestrel
Nucresiran
Obesity medication with liraglutide or semaglutide
Octreotide
Olanzapine
Olatorepatide
Olipudase Alfa
Omaveloxolone
Omeprazole
Optimized Prophylactic IM Therapy
Oral GLP-1
Orforglipron
LY3502970
Other drugs
Oxaliplatin
Oxycodone Hydrochloride
Palbociclib
palcebo
Pancreatic Polypeptide
Pancreatin
Pancrelipase Lipase
Paracetamol
Pasireotide
PATAS Trifluoroacetate
Patiromer
Pegloticase
Pegozafermin
Pegtibatinase
Pembrolizumab
Petrelintide
PF-08642534
PF-08642534
PF-08653944
PF-08653945
PG-102
Pharmacokinetics study
Phentermine
Phentermine-Topiramate
Pioglitazone Hydrochloride
Pitavastatin Calcium
PJ009
Plozasiran
PM577a
Polyethylene Glycol 3350
Polypill
Pomalidomide
PORT-77
PORT-77
PPI deprescribing
Pramlintide
Prazosin Hydrochloride
Pre-study basal insulin
Prednisone
Pregabalin
Pridopidine
Progerinin
Prophylactic Immunomodulatory (IM) Therapy
PRX-115
PRX-115
PYC-001
PYC-001
r-glucagon
Rabeprazole Sodium
Ranibizumab
RAPA-501 Autologous T stem cells
RAPA-501 Autologous T stem cells
Rapid ESC-guideline based secondary prevention following myocardial infaction
RAY1225
RBD5044
RBD5044
RE104 for
RE104 for
Receptor Agonists
Recombinant human hyaluronidase PH20
REGN20934
REGN20934
Regular Insulin
relacorilant
Relaxin
REMD-477
Retatrutide
LY3437943
RGB-5088
Ribupatide
KAI-9531 / HRS9531
Rimegepant
Ritlecitinib
Rituximab
RN3161
RO7795081
RO7795081
Romosozumab
Rosuvastatin 1
Rosuvastatin 2
Rosuvastatin 3
Rosuvastatin 4
Rosuvastatin Calcium
RP-A501
RP-A501
Sacubitril/Valsartan
Saline Infusion
Sanggua
Sapropterin Dihydrochloride
Scopolamine patch
Semaglutide
Semaglutide (Wegovy)
semaglutide or tirzepatide
Sepiapterin
SGLT2i
SGLT2i or GLP-1RA
SGT-212
SGT-212
SHR-1918
SHR-1918
SHR3824
Sirolimus
Sitagliptin
Sloe
Sodium Bicarbonate
Sodium Chloride
Solbinsiran
stem cell transplantation
STX-1150
STX-1150
Sufentanil Citrate
Sugammadex Sodium
Sulfasalazine
Tacrolimus
TCC1727 tablet 120mg
Teduglutide
Tegileridine
Teplizumab
Teriparatide
Test drug CB03-154 group
Test drug CB03-154 group
TETA 4HCl formulation
TEV-53408
TEV-53408
Thiazolidinedione
Thiotepa
THRV-1268
Tirzepatide
LY3298176
TIX100
TIX100
Torsemide
TP04HN106
TP04HN106
TQF3250 capsules
Transplant of stem cells with CD3+/CD19+ depletion
Treatment Plan 1: Stratum 1
treatment T
Tris-hydroxymethyl Aminomethane
Tylenol Suspension
UBT251
UBT251 group
UBT251 group
UBT38006
UBT38006
Usual insulin treatment
UX111
UX111
Valsartan
Vamifeport
VCT220
Velpatasvir
Venetoclax
Venofer Per
Vericiguat
VERVE-102
VERVE-102
Veverimer
VHB937
Vibegron
Vicadrostat
Vildagliptin
Vildagliptin 50 MG
VK2735
VK2735
VK2735 Drug
VK2735 Drug
VK3019
VK3019
Vutrisiran
VVD-133214
VVD-133214
XTL6001
XW003 injection
Zenagamtide
Zodasiran
Zofran
Zoledronic Acid /Bag Infusion
zovaglutide Arm 1
[14C]HRS9531
[68Ga] Ga-DO3A-VS-Cys40-Exendin-4
[68Ga] Ga-DO3A-VS-Cys40-Tuna-2
[Part 1.1] IDG-16177
[Part 2] IDG-16177
[Part1.2] IDG-16177
1.5 mg or 2.0 mg CJC-1134-PC
14C Tirzepatide
2 OGTTs with and without GLP-1 analogue
200 mg FHND1002(fasting)
200mg FHND1002
AAE581
AC-201
AC2307
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
AD-233A
AD-233A
AD-233B
AD-233B
AD-233C
AD-233C
AD-233D
AD-233D
Adjustment of insulin doses CFT
Adjustment of insulin doses DAR
AEB1102
AEB1102
Albiglutide
alirocumab SAR236553
ALN-6457
ALN-6457
ALT001 /kg
ALT001 /kg
ALXN1840
ALXN2220
ALXN2220
AMG 513
AMG 513
Amycretin
AP-101
AP026 (TQA2226) for injection
AR882
AR882
Arhalofenate
ASP1941
AT673 high dose
AT673 high dose
AT673 low dose
AT673 low dose
ATI-105
ATI-105
ATR-258
ATR-258
AutoCD6-CAR Treg cells
AZD0186
AZD1656
AZD6234 in combination with AZD9550
AZD6234 in combination with AZD9550
B cell infusion
BIIB147
BIIB147
BM2216 Extended-Release Tablets
BMS-823778
BMS-852927
bremelanotide
BXT-51072
BYM338 10 mg/kg
BZA 20 mg/CE 0.45 mg
C-peptide proinsulin ratio
C13 Hyperpolarized pyruvate
C13 Hyperpolarized pyruvate
Cadisegliatin
CCX140-B
CD34 Stem Cell Selection Therapy
CDX 6114
CE-326,597 100 mg QD
CER-001
Chiglitazar , dose 1
Chiglitazar , dose 2
Chiglitazar/Metformin fixed-dose combination , dose 1
Chiglitazar/Metformin fixed-dose combination , dose 2
CIL001
CJC-1134-PC
CKD-386
CKD-501
CKD-501, D745, D150
CKD-519 100mg
Closed loop with sensor, Insulin and Liraglutide
Cohort A: ORMD-0801
Combined vitamin D₃ and K₂ supplementation
COR-1004 + COR-2003
COR-1004 + COR-2003
COR-2003
COR-2003
Cotadutide
CRB-913
CRB-913
CTP-499
Danuglipron
Dasiglucagon
Dazucorilant
DD01
Dihuang Baoyuan Granules
DISC-1459
DLBS1033
Donafenib + Tislelizumab
DR10624
DR10624
Efpeglenatide
elamipretide (MTP-131) 1% topical ophthalmic solution
EPI-743 200 mg
ETC-1002
ethinyl estradiol and levonorgestrel; exenatide
Etonogestrel/ethinyl estradiol vaginal ring
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
Exenatide (GLP-1RA) or Liraglutide
Exenatide, Liraglutide
Experimental: GLP1-RA (exenatide) administration
Ezetimibe STP
Fecal microbiota transplantation delivery through
Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/
Flexeril Product
G-Pump™
Garetosmab
GIP + alanine
GIP Bolus
GIP Clamp
GIP/GLP-1a
GLP-1 High Dose
GLP-1 Low Dose
GLP-1 Mid-Range Dose
GLP-1 Receptor Agonists + Behavioral modification
GLP-1-9,36 infusion
Glucagon 12.5ng/kg/min
Glucagon 12.5ng/kg/min and 0.9% saline
Glucagon hydrochloride
Glucagon IM
Glucagon Nasal Powder
Glucagon Nasal Powder [Baqsimi]
Glucagon RTU
Glucagon-Like Peptide- 1 (GLP-1) infusion
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Glycerol Tributyrate
GNR-055 1.0-2.0- /kg
GNR-055 1.0-2.0- /kg
GS1168
GS1168
GSK189075
GSK2315698
GSK2398852
gut-brain axis (GLP-1)-activating food carbohydrate
GW869682
GZ402665
GZR102
HDG1901
HE3286
High tocotrienols group
HK-001
HK-001
HR17031
HR20031 FDC
HRS-1301 Tablet
HRS-1596
HRS-1596
HS-10582
HSG4112
Human apotransferrin
Human GLP-1 (7-36) amide
I.v. NNC 0113-0987
IM Glucagon
Immedate Release Torsemide
Increasing doses of GLP-1
INGAP-Peptide
insulin degludec/liraglutide
Insulin glargine HOE901
INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Insulin Lispro SAR342434
Insulin monotherapy with premixed insulin NPH 30/70
Intranasal glucagon
Intravenous glucagon
ITCA 650 Osmotic Mini Pump 20/60 mcg/day
ITCA 650 Osmotic Mini Pump 60 mcg/day
JNJ-64565111
JNJ-64565111 Dose Level 1
JNJ-64565111 Dose Level 2
JNJ-64565111 Dose Level 3
JR-141
JR-141
JS002
JTT-130
KAI-7535
KQ-791
LAM-002A
LAM-002A
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Laroprovstat STP
Laroprovstat/ezetimibe FCDP
Laroprovstat/ezetimibe FCDP-slow variant
Leptin plus Pramlintide
Lilly Glucagon
LIPO-102
Liraglutide for 26 weeks
Liraglutide injection,RD12014
Liraglutide Pen Injector [Saxenda]
Lispro Prandial Insulin
Liver-Expressed Antimicrobial Peptide 2
Low tocotrienols group
LY2393910
LY2403021
LY2409021
LY2922083
LY2963016
LY3884961
LY3884961
LY3938577
LY3938577
LY4064912
LY4064912
MBL949
MBX-2982
MBX-2982
MDR-001
MEDI0382
MEDI0382 Formulation 2
MEDI0382 Formulation 3
Metformin , dose 1
Metformin , dose 2
Metformin + Personalized diet
metformin and liraglutide
Metformin with Semaglutide
Metformin XR plus liraglutide
Metformin-GLP-1 Receptor Agonist
Mini-glucagon
Miscellany
MK-1403 + additive coformulation
MK-1403 + additive coformulation
MK-4082 Formulation 1
MK-4082 Formulation 1
MK-4082 Formulation 2
MK-4082 Formulation 2
MK-4082 Formulation 4
MK-4082 Formulation 4
MK0557
MK0653, ezetimibe
MK0653, ezetimibe / Duration of Treatment: 6 Weeks
MKC253 Inhalation Powder
morphine and glucagon
MSDC-0602K
MT-1186
MWN117
MWN117
Naronapride
Nasal Glucagon
native glp-1
Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
NBIP-01435
NBIP-01435
NEX-22A, a prolonged release formulation of liraglutide
NGM282
NGM313
NM-002
NNC 0123-0000-0338
NNC0174-0833
NNC0363-0845
NNC0471-0119 H
NNC0471-0119 H
NNC0487-0111 subcutanous
NNC0487-0111 subcutanous
NNC0638-0355
NNC0638-0355
NNC9204-1513
non-GLP weight loss medication
NPO-11
NT-0796
NT-0796
Omarigliptin
Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Gl
oral NNC 0113-0987
Other DPP4-i
Para-probiotic care
Part C: RM-718
Part C: RM-718
Part D: RM-718
Part D: RM-718
PB-119
Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon
Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control
Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon
Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control
Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon
Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control
Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control
PF-04603629
PF-04950615
PF-06291874
PF-06743649
PF-07081532
Phentermine/Topiramate ER
Pioglitazone plus exenatide
PPI-1011
PPI-1011
Pramlintide and glucagon
Premixed Lyumjev
Prohibitin-TP01
rAAV9-CMV-hNAGLUop
RDD to Palynziq
rExenatide-4
RN316
RNS60
RO4998452
RO7204239
RO7204239
ROSE-010 150 mcg
Routine biological monitoring
Routine Lipid Management
RTX001
RTX001
SAP-001
SAR425899
SAR438544
SB-509
SB-751689
Semagludtide
SLS-005
SP2086
SYH2069 Injection
TAG adjunctive treatment group
TAK-101
TAK-101
TAK-875
Tazbentetol
Test bacterial peptide: RUCILP
THR-149 dose level 1
THR-149 dose level 2
THR-149 dose level 3
TK006
Tralesinidase alfa
treatment R
Treatment with iron
Treatment with sucrosomial iron
Trizepatide
TTI-0102
TTI-0102
UBX1325
Ultra-rapid insulin
VELA-101
VELA-101
Velaglucerase beta
Venetoclax MTD with Dexamethasone
very low dose (VLD) glucagon
Vitamin D₃ alone
VTX3232
VTX3232
VTX3232 in combination with semaglutide
VTX3232 in combination with semaglutide
VX-264
VX-264
